Marilyn K Glassberg Csete

Professor of Clinical

  • 4589 Citations
1982 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Marilyn K Glassberg Csete is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Idiopathic Pulmonary Fibrosis Medicine & Life Sciences
Lymphangioleiomyomatosis Medicine & Life Sciences
Lung Medicine & Life Sciences
Endothelin-1 Medicine & Life Sciences
Mesenchymal Stromal Cells Medicine & Life Sciences
Lung Diseases Medicine & Life Sciences
Placebos Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1982 2019

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Glassberg Csete, M. K., Nathan, S. D., Lin, C. Y., Morgenthien, E. A., Stauffer, J. L., Chou, W. & Noble, P. W., Jan 1 2019, (Accepted/In press) In : Advances in Therapy.

Research output: Contribution to journalArticle

Open Access
Idiopathic Pulmonary Fibrosis
Hemorrhage
Placebos
Preexisting Condition Coverage
Fibrinolytic Agents

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)

Glassberg, M. K., Nathan, S. D., Lin, C. Y., Morgenthien, E. A., Stauffer, J. L., Chou, W. & Noble, P. W., Oct 1 2019, In : Advances in Therapy. 36, 10, p. 2927-2929 3 p.

Research output: Contribution to journalComment/debate

Open Access
Idiopathic Pulmonary Fibrosis
Publications
Color
Hemorrhage
Therapeutics
2 Citations (Scopus)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis

Costabel, U., Albera, C., Glassberg Csete, M. K., Lancaster, L. H., Wuyts, W. A., Petzinger, U., Gilberg, F., Kirchgaessler, K. U. & Noble, P. W., Mar 12 2019, In : Respiratory Research. 20, 1, 55.

Research output: Contribution to journalArticle

Open Access
Idiopathic Pulmonary Fibrosis
Safety
pirfenidone
Lung
Therapeutics

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis

Glassberg, M. K., Wijsenbeek, M. S., Gilberg, F., Petzinger, U., Kirchgaessler, K. U. & Albera, C., Sep 1 2019, In : The European respiratory journal. 54, 3

Research output: Contribution to journalLetter

Open Access
Idiopathic Pulmonary Fibrosis
Dyspnea
pirfenidone
1 Citation (Scopus)

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis

Nathan, S. D., Costabel, U., Glaspole, I., Glassberg Csete, M. K., Lancaster, L. H., Lederer, D. J., Pereira, C. A., Trzaskoma, B., Morgenthien, E. A., Limb, S. L. & Wells, A. U., Jan 1 2019, In : CHEST.

Research output: Contribution to journalArticle

Open Access
Idiopathic Pulmonary Fibrosis
Disease Progression
Placebos
Incidence
Hospitalization